The 18.3 Data Release includes updates from longitudinal studies, MODEL-AD data, and a web application.

Human

  • Drug Repurposing in Alzheimer’s Disease (DRIAD)
    This is a web application that evaluates gene sets for their ability to predict the progression of Alzheimer’s disease (AD). It utilizes expression data from post-mortem samples of AD patients collected by the AMP-AD consortium, using data from the ROSMAP and MSBB studies. See Rodriguez and Hug et.al.

  • The ROSMAP_CognitiveResilience Study
    This study provides proteomics data and bulk brain RNAseq data from Brodmann Areas 6 and 37 from two longitudinal studies of aging – the Religious Orders Study and the Memory and Aging Project (ROSMAP). Included are ROSMAP individuals who came to autopsy without dementia, but with high levels of Alzheimer’s disease pathology. A future release will include proteomics from synaptic fractions and 3D dendritic spine morphometry on these individuals.

    • This release adds:
      • Quantitative proteomics data (TMT) for 128 individuals from BA6 and BA37

  • The DiCAD Study
    This study provides longitudinal clinical and  imaging data, as well as proteomics, metabolomics, GWAS, and plasma biomarker data on a cohort of 200 community dwelling late middle-aged Hispanic individuals without dementia. 

    • This release adds:
      • Updated clinical assessments, laboratory data, MRI and PET imaging data,  and data description documentation
      • GWAS data
      • Plasma AD biomarkers from single-molecule array (SiMoA) immunoassay
      • LC-MSMS metabolomics data
      • Proximity extension assay proteomics data
      • Reformatted and updated individual, biospecimen, and assay metadata files for all specimens and assays
      • Previous APOE genotype data was moved to the individual metadata file

Models

  • The UCI_5XFAD Study
    This study provides deep phenotyping data from the 5XFAD mouse model

    • This release updates the Abeta40 and Abeta42 measurements in plasma from mice at 4, 8, 12, and 18 months (assay=electrochemiluminescence). The previous file had an incorrect set of mice.

  • The  Jax.IU.Pitt_PrimaryScreen Study
    This study provides an initial molecular and behavioral characterization of mouse models of Late-Onset Alzheimer’s Disease as part of the MODEL-AD Program. Provided is gene expression as measured by a NanoString nCounter® Mouse AD pane, and frailty assessment

      • This release updates the following:
        • The biospecimen file  by correcting the tissue used for the gene expression from ‘whole brain’ to ‘right cerebral hemisphere’. 
        • The removal of 8 NanoString nCounter® output files with measurements from samples that are not part of the study.